• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低成骨不全患儿骨折发生率:支具对双膦酸盐治疗的作用

Reducing fracture incidence in children with osteogenesis imperfecta: contribution of orthotics to bisphosphonates treatment.

作者信息

Eylon S, Kornitzer E, Wever C, Rigbi A, Weiss P L, Meyer S

机构信息

ALYN Pediatric and Adolescent Rehabilitation Center, Jerusalem, Israel.

Beit Berl College, Faculty of Education, Kfar-Saba, Israel.

出版信息

Disabil Rehabil. 2024 Apr;46(7):1416-1421. doi: 10.1080/09638288.2023.2198259. Epub 2023 Apr 17.

DOI:10.1080/09638288.2023.2198259
PMID:37067232
Abstract

PURPOSE

To determine whether there was a reduction in fracture incidence amongst children with OI who were treated with both bisphosphonates and orthoses.

OBJECTIVE

Was there an additional reduction in fracture incidence amongst children with Osteogenesis Imperfecta (OI) treated with both bisphosphonates and Hip-Knee-Ankle-Foot-Orthosis (HKAFO)?

MATERIALS AND METHODS

Of the 129 OI patients treated from 1990 to 2017, retrospective data from 48 patients who participated in the bisphosphonates-orthosis regime were analyzed including the incidence of fractures and modalities of fracture treatment.

RESULTS

Bisphosphonates usage was more frequent than bracing and there were more positive changes (smaller or equal number of fractures each year) than negative changes (more fractures each year); negative changes were scarce, explained by non-compliance with the use of bracing. Poisson regression models were significant for positive changes, whereas the interaction between them was borderline significant. The main finding is that the association between bisphosphonates usage and the number of positive changes was stronger among the patients who used braces more frequently and weaker among patients who used bracing less frequently.

CONCLUSIONS

Bracing of OI patients has an additive effect on bisphosphonate treatment in fracture prevention which should lead to the reconsideration of a hybrid approach to OI management.

摘要

目的

确定接受双膦酸盐和矫形器治疗的成骨不全症(OI)患儿的骨折发生率是否降低。

目标

接受双膦酸盐和髋-膝-踝-足矫形器(HKAFO)治疗的成骨不全症(OI)患儿的骨折发生率是否有额外降低?

材料与方法

对1990年至2017年接受治疗的129例OI患者进行回顾性分析,分析48例参与双膦酸盐-矫形器治疗方案患者的数据,包括骨折发生率和骨折治疗方式。

结果

双膦酸盐的使用比支具更频繁,与骨折数量每年增加(负面变化)相比,骨折数量每年减少或持平(正面变化)的情况更多;负面变化很少,原因是未坚持使用支具。泊松回归模型对正面变化具有显著意义,而两者之间的相互作用接近显著。主要发现是,在更频繁使用支具的患者中,双膦酸盐使用与正面变化数量之间的关联更强,而在较少使用支具的患者中则较弱。

结论

对OI患者使用支具在预防骨折方面对双膦酸盐治疗具有附加作用,这应促使人们重新考虑对OI采用综合治疗方法。

相似文献

1
Reducing fracture incidence in children with osteogenesis imperfecta: contribution of orthotics to bisphosphonates treatment.降低成骨不全患儿骨折发生率:支具对双膦酸盐治疗的作用
Disabil Rehabil. 2024 Apr;46(7):1416-1421. doi: 10.1080/09638288.2023.2198259. Epub 2023 Apr 17.
2
A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.成骨不全症患者在儿童期或成年期开始使用双磷酸盐治疗后的生活质量、功能和骨骼结局的对比研究。
Bone. 2018 Aug;113:137-143. doi: 10.1016/j.bone.2018.05.021. Epub 2018 May 19.
3
Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.双膦酸盐预防成骨不全骨折:安慰剂对照试验的荟萃分析
J Bone Miner Res. 2015 May;30(5):929-33. doi: 10.1002/jbmr.2410.
4
Bisphosphonate therapy for osteogenesis imperfecta.用于成骨不全的双膦酸盐治疗
Cochrane Database Syst Rev. 2014 Jul 23(7):CD005088. doi: 10.1002/14651858.CD005088.pub3.
5
Bisphosphonate therapy for osteogenesis imperfecta.用于成骨不全症的双膦酸盐治疗
Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4.
6
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.利塞膦酸盐治疗 I 型成骨不全症成人患者:增加骨密度和减少骨转换,但骨折率仍居高不下。
Osteoporos Int. 2012 Jan;23(1):285-94. doi: 10.1007/s00198-011-1658-2. Epub 2011 Jul 8.
7
Bisphosphonate therapy for osteogenesis imperfecta.用于成骨不全的双膦酸盐治疗
Cochrane Database Syst Rev. 2008 Oct 8(4):CD005088. doi: 10.1002/14651858.CD005088.pub2.
8
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.患者处理:成骨不全症成人骨折风险降低的药物治疗方法。
J Clin Endocrinol Metab. 2023 Jun 16;108(7):1787-1796. doi: 10.1210/clinem/dgad035.
9
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.79名患有I型、III型和IV型成骨不全症的瑞典儿童接受帕米膦酸盐治疗后的骨折率降低、药物遗传学及骨密度反应
Bone. 2016 Jun;87:11-8. doi: 10.1016/j.bone.2016.02.015. Epub 2016 Mar 5.
10
Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment.成骨不全症患者股骨干骨折:特征及与双膦酸盐治疗的关系
J Bone Miner Res. 2017 May;32(5):1034-1039. doi: 10.1002/jbmr.3071. Epub 2017 Feb 28.